Claims for Patent: 9,549,895

Summary for Patent: 9,549,895

Title:	Methods and compositions for preserving the viability of photoreceptor cells
Abstract:	Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous MCP-1, a MCP-1 antagonist, a substance capable of suppressing endogenous TNF-alpha, a TNF-alpha antagonist, a substance capable of suppressing endogenous IL-1 beta, an IL-1 beta antagonist, a substance capable of inducing endogenous bFGF, exogenous bFGF, a bFGF mimetic, and combinations thereof, to a mammal having an eye with retinal detachment. The neuroprotective agent maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment.
Inventor(s):	Nakazawa; Toru (Sendai Miyagi, JP)
Assignee:	Massachusetts Eye and Ear Infirmary (Boston, MA)
Application Number:	11/587,022
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,549,895
Patent Claims:	1. A method of preserving the viability of photoreceptor cells disposed within a retina of a mammalian eye following retinal detachment, the method comprising: administering to a mammal having an eye in which a region of the retina has been detached an amount of a neuroprotective agent selected from the group consisting of etanercept, an anti-TNF-alpha antibody, and combinations thereof sufficient to preserve the viability of photoreceptor cells disposed within the region of the detached retina. 2. The method of claim 1, wherein the neuroprotective agent is administered to the mammal prior to reattachment of the region of detached retina. 3. The method of claim 1 or 2, wherein the neuroprotective agent is administered to the mammal after reattachment of the region of detached retina. 4. The method of claim 1, wherein the neuroprotective agent is administered locally or systemically. 5. The method of claim 1, wherein a plurality of neuroprotective agents are administered to the mammal. 6. The method of claim 5, wherein the neuroprotective agents are administered locally or systemically. 7. The method of claim 4 or 6, wherein at least one neuroprotective agent is administered by intraocular, intravitreal, or transcleral administration. 8. The method of claim 1, wherein the neuroprotective agent reduces the number of photoreceptor cells in the region that die following retinal detachment. 9. The method of claim 1, wherein the retinal detachment occurs as a result of a retinal tear, retinoblastoma, melanoma, diabetic retinopathy, uveitis, choroidal neovascularization, retinal ischemia, pathologic myopia, or trauma. 10. The method of claim 1, wherein the neuroprotective agent is etanercept. 11. The method of claim 1, wherein the neuroprotective agent is an anti-TNF-alpha antibody. 12. A method of preserving the viability of photoreceptor cells disposed within a retina of a mammalian eye following retinal detachment, the method comprising: administering to a mammal's retina, the mammal having an eye in which a region of the retina has been detached, an amount of a neuroprotective agent selected from the group consisting of etanercept, an anti-TNF-alpha antibody, and combinations thereof sufficient to preserve the viability of photoreceptor cells disposed within the region of the detached retina. 13. The method of claim 12, wherein at least one neuroprotective agent is administered by intraocular, intravitreal, or transcleral administration. 14. The method of claim 12, wherein the neuroprotective agent is administered to the mammal prior to reattachment of the region of detached retina. 15. The method of claim 12, wherein the neuroprotective agent is administered to the mammal after reattachment of the region of detached retina. 16. The method of claim 12, wherein the retinal detachment occurs as a result of a retinal tear, retinoblastoma, melanoma, diabetic retinopathy, uveitis, choroidal neovascularization, retinal ischemia, pathologic myopia, or trauma. 17. The method of claim 12, wherein the neuroprotective agent is etanercept. 18. The method of claim 12, wherein the neuroprotective agent is an anti-TNF-alpha antibody.

Details for Patent 9,549,895

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2024-04-23
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2024-04-23
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2024-04-23